scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1039523511 |
P356 | DOI | 10.1186/2050-6511-13-14 |
P932 | PMC publication ID | 3517742 |
P698 | PubMed publication ID | 23136834 |
P5875 | ResearchGate publication ID | 233382799 |
P50 | author | Deirdre M D'Arcy | Q57250442 |
P2093 | author name string | Owen I Corrigan | |
Eoin Casey | |||
Maria B Donnelly | |||
Caitriona M Gowing | |||
P2860 | cites work | A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients | Q28325426 |
Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa | Q34290150 | ||
Population pharmacokinetics of amikacin in critically ill patients | Q35125654 | ||
Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration | Q35270646 | ||
Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration | Q35810241 | ||
Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy | Q37008814 | ||
Antibiotic resistance--what's dosing got to do with it? | Q37205795 | ||
Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis | Q37461431 | ||
Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 | ||
Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. | Q52071390 | ||
Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy | Q64126632 | ||
Implications of augmented renal clearance in critically ill patients | Q64129339 | ||
Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients | Q67779622 | ||
Pharmacokinetics of amikacin during continuous veno-venous hemofiltration | Q68796364 | ||
Amikacin pharmacokinetics: wide interpatient variation in 98 patients | Q70129560 | ||
Amikacin pharmacokinetics during continuous veno-venous hemofiltration | Q70141346 | ||
Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia | Q70386358 | ||
Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition | Q70937793 | ||
Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis | Q73425751 | ||
P921 | main subject | hemodiafiltration | Q3144940 |
pharmacokinetics | Q323936 | ||
amikacin | Q408529 | ||
P304 | page(s) | 14 | |
P577 | publication date | 2012-11-08 | |
P1433 | published in | BMC pharmacology & toxicology | Q27724429 |
P1476 | title | An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration | |
P478 | volume | 13 |
Q40809870 | A high-dose aminoglycoside regimen combined with renal replacement therapy for the treatment of MDR pathogens: a proof-of-concept study. |
Q33939050 | Amikacin pharmacokinetics during continuous veno-venous hemodialysis |
Q86490988 | Gentamicin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration (CVVHDF) |
Q49894608 | Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients |
Q37119964 | Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy |
Q88214372 | What is new in the use of aminoglycosides in critically ill patients? |
Search more.